Nuvalent Announces Pricing of Public Offering of Common Stock
Nuvalent, Inc. (NASDAQ: NUVL), a clinical-stage biopharmaceutical company engaged in developing targeted therapies for cancer, has unveiled the pricing details for their public offering of Class A common stock. The shares, priced at $101.00 each, represent a significant step forward in capitalizing on their innovative therapeutic approach.
Details of the Offering
Nuvalent will offer approximately 4,950,496 shares through this underwritten public offering, anticipating gross proceeds around $500 million. However, it's important to note that these figures are before underwriting discounts and commissions as well as related expenses. The offering is set to close on a date dependent on customary closing conditions.
Participation of Selling Stockholders
Additionally, two prominent entities, Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund IV, L.P., participating as Selling Stockholders, have extended an option for underwriters to acquire up to 742,574 additional shares at the public offering price. Notably, Nuvalent will not obtain any proceeds from the sale of shares by these Selling Stockholders.
Management of the Offering
The underwriting of this offering is being managed by a group of esteemed financial institutions including J.P. Morgan, Jefferies, TD Cowen, and Cantor Fitzgerald. Their experience in the field is expected to facilitate a successful transaction that could significantly bolster Nuvalent's financial position.
Regulatory Compliance and Registration
The shares are being offered under a shelf registration statement that has already been approved by the Securities and Exchange Commission (SEC), ensuring compliance with regulatory standards. A detailed prospectus will accompany this offering, providing potential investors with the necessary information regarding terms and conditions.
About Nuvalent, Inc.
Nuvalent, Inc. (NASDAQ: NUVL) is committed to developing targeted therapies that address the pressing needs of cancer patients. With their expertise in chemistry and drug design, they focus on creating small molecules aimed at overcoming the challenges associated with existing cancer treatments. Their portfolio includes investigational treatments targeting ROS1-positive, ALK-positive, and HER2-altered forms of non-small cell lung cancer, along with multiple research programs in the early stages.
Frequently Asked Questions
What is the main purpose of Nuvalent's public offering?
The public offering aims to raise funds essential for advancing Nuvalent's cancer therapies and supporting ongoing research and development initiatives.
How many shares are being offered in this public offering?
Nuvalent is offering approximately 4,950,496 shares of Class A common stock in this public offering.
What is the pricing of the offered shares?
The shares are priced at $101.00 each for the public offering.
Who are the underwriters involved in this offering?
The offering is being managed by J.P. Morgan, Jefferies, TD Cowen, and Cantor Fitzgerald.
What are the future prospects for Nuvalent after this offering?
Following this offering, Nuvalent aims to leverage the raised funds to enhance their research on targeted cancer therapies and to ensure the launch of their innovative treatment options.
